Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 49 | 2023 | 1427 | 7.810 |
Why?
|
| Brain | 40 | 2023 | 1801 | 4.900 |
Why?
|
| White Matter | 11 | 2022 | 157 | 4.730 |
Why?
|
| Aging | 36 | 2023 | 1727 | 4.530 |
Why?
|
| Cognitive Dysfunction | 32 | 2023 | 1095 | 4.000 |
Why?
|
| Aged | 118 | 2023 | 10047 | 3.750 |
Why?
|
| Alzheimer Disease | 30 | 2023 | 2132 | 3.570 |
Why?
|
| Neuropsychological Tests | 61 | 2023 | 1316 | 3.540 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 427 | 3.280 |
Why?
|
| Magnetic Resonance Imaging | 38 | 2023 | 1311 | 2.880 |
Why?
|
| Cognition Disorders | 19 | 2020 | 1055 | 2.840 |
Why?
|
| Diffusion Tensor Imaging | 12 | 2023 | 85 | 2.780 |
Why?
|
| Humans | 147 | 2023 | 30999 | 2.590 |
Why?
|
| Female | 103 | 2023 | 16985 | 2.540 |
Why?
|
| Male | 100 | 2023 | 16447 | 2.500 |
Why?
|
| Hypertension | 7 | 2022 | 288 | 2.350 |
Why?
|
| Depression | 8 | 2020 | 481 | 2.260 |
Why?
|
| Executive Function | 21 | 2023 | 125 | 2.220 |
Why?
|
| Middle Aged | 72 | 2023 | 10197 | 2.100 |
Why?
|
| Blood Pressure | 8 | 2022 | 261 | 2.000 |
Why?
|
| Aged, 80 and over | 55 | 2023 | 5189 | 1.930 |
Why?
|
| Verbal Learning | 11 | 2021 | 39 | 1.860 |
Why?
|
| Dementia | 16 | 2023 | 560 | 1.830 |
Why?
|
| Memory Disorders | 7 | 2018 | 177 | 1.780 |
Why?
|
| Acculturation | 3 | 2023 | 40 | 1.780 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 93 | 1.760 |
Why?
|
| Memory, Short-Term | 11 | 2023 | 104 | 1.750 |
Why?
|
| Connectome | 5 | 2021 | 14 | 1.740 |
Why?
|
| Risk Factors | 26 | 2023 | 2588 | 1.610 |
Why?
|
| Gray Matter | 5 | 2023 | 59 | 1.590 |
Why?
|
| Prefrontal Cortex | 7 | 2016 | 152 | 1.570 |
Why?
|
| Neuroimaging | 10 | 2023 | 144 | 1.510 |
Why?
|
| Health Literacy | 3 | 2023 | 108 | 1.480 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 148 | 1.400 |
Why?
|
| Residence Characteristics | 4 | 2021 | 226 | 1.340 |
Why?
|
| Decision Making | 6 | 2023 | 237 | 1.300 |
Why?
|
| Public Health | 6 | 2021 | 68 | 1.200 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 82 | 1.200 |
Why?
|
| Brain Mapping | 10 | 2021 | 190 | 1.190 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 89 | 1.100 |
Why?
|
| United States | 18 | 2021 | 2375 | 1.070 |
Why?
|
| Depressive Disorder | 5 | 2017 | 192 | 1.070 |
Why?
|
| Cohort Studies | 19 | 2023 | 2042 | 1.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 190 | 1.040 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2013 | 40 | 1.040 |
Why?
|
| Depressive Disorder, Major | 9 | 2018 | 108 | 1.040 |
Why?
|
| Tryptophan | 5 | 2014 | 13 | 1.040 |
Why?
|
| Memory | 10 | 2021 | 328 | 1.010 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 270 | 0.990 |
Why?
|
| Cognitive Aging | 3 | 2020 | 87 | 0.960 |
Why?
|
| Exercise | 7 | 2022 | 507 | 0.940 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 1009 | 0.940 |
Why?
|
| Hippocampus | 9 | 2022 | 280 | 0.940 |
Why?
|
| Stroke | 5 | 2023 | 315 | 0.940 |
Why?
|
| Educational Status | 5 | 2023 | 312 | 0.920 |
Why?
|
| Psychomotor Performance | 9 | 2020 | 218 | 0.910 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 31 | 0.910 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 149 | 0.870 |
Why?
|
| Spatial Processing | 2 | 2021 | 8 | 0.870 |
Why?
|
| Linear Models | 6 | 2020 | 273 | 0.870 |
Why?
|
| Income | 3 | 2021 | 80 | 0.840 |
Why?
|
| Mental Recall | 7 | 2020 | 72 | 0.840 |
Why?
|
| Adult | 28 | 2023 | 8933 | 0.820 |
Why?
|
| Social Participation | 1 | 2022 | 12 | 0.810 |
Why?
|
| Genotype | 5 | 2020 | 428 | 0.810 |
Why?
|
| Crime Victims | 1 | 2022 | 25 | 0.810 |
Why?
|
| Leukoaraiosis | 3 | 2012 | 8 | 0.800 |
Why?
|
| Blood Glucose | 2 | 2022 | 120 | 0.790 |
Why?
|
| Clinical Protocols | 1 | 2022 | 67 | 0.780 |
Why?
|
| Analysis of Variance | 10 | 2017 | 324 | 0.770 |
Why?
|
| Anisotropy | 5 | 2023 | 62 | 0.770 |
Why?
|
| Optimism | 1 | 2021 | 2 | 0.740 |
Why?
|
| Psychology | 1 | 2021 | 24 | 0.740 |
Why?
|
| Family Relations | 1 | 2021 | 11 | 0.740 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1504 | 0.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 213 | 0.720 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 195 | 0.720 |
Why?
|
| Social Segregation | 1 | 2020 | 8 | 0.720 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 44 | 0.710 |
Why?
|
| Social Environment | 1 | 2021 | 87 | 0.710 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 88 | 0.700 |
Why?
|
| Racism | 1 | 2021 | 36 | 0.700 |
Why?
|
| Cholesterol | 2 | 2019 | 54 | 0.700 |
Why?
|
| Loneliness | 1 | 2021 | 61 | 0.700 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 101 | 0.690 |
Why?
|
| Social Capital | 1 | 2020 | 5 | 0.690 |
Why?
|
| Triglycerides | 1 | 2019 | 47 | 0.670 |
Why?
|
| Dyslipidemias | 1 | 2019 | 23 | 0.660 |
Why?
|
| Social Support | 1 | 2021 | 194 | 0.660 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 61 | 0.660 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 4 | 0.650 |
Why?
|
| Mental Processes | 1 | 2019 | 19 | 0.650 |
Why?
|
| Life Style | 1 | 2021 | 226 | 0.650 |
Why?
|
| Cultural Diversity | 1 | 2019 | 27 | 0.640 |
Why?
|
| Multilingualism | 1 | 2019 | 11 | 0.640 |
Why?
|
| Community Health Services | 1 | 2019 | 31 | 0.630 |
Why?
|
| Insulin Resistance | 1 | 2019 | 60 | 0.630 |
Why?
|
| Neural Pathways | 9 | 2018 | 83 | 0.620 |
Why?
|
| Prospective Studies | 13 | 2022 | 1898 | 0.620 |
Why?
|
| Stress, Psychological | 1 | 2021 | 254 | 0.610 |
Why?
|
| Independent Living | 6 | 2022 | 321 | 0.610 |
Why?
|
| Phenotype | 2 | 2019 | 379 | 0.610 |
Why?
|
| Kidney | 1 | 2019 | 181 | 0.600 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2023 | 225 | 0.590 |
Why?
|
| Psychological Trauma | 1 | 2017 | 3 | 0.580 |
Why?
|
| Affect | 3 | 2013 | 66 | 0.560 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 43 | 0.550 |
Why?
|
| Serotonin | 4 | 2014 | 37 | 0.540 |
Why?
|
| Individuality | 1 | 2016 | 23 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 463 | 0.530 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 14 | 0.480 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 10 | 0.480 |
Why?
|
| Thinking | 1 | 2014 | 14 | 0.480 |
Why?
|
| Verbal Behavior | 5 | 2009 | 20 | 0.470 |
Why?
|
| Obesity | 4 | 2023 | 307 | 0.460 |
Why?
|
| Sex Factors | 6 | 2020 | 511 | 0.450 |
Why?
|
| Age Factors | 8 | 2020 | 873 | 0.450 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 1211 | 0.450 |
Why?
|
| Frontal Lobe | 5 | 2018 | 83 | 0.440 |
Why?
|
| Vascular Diseases | 2 | 2013 | 52 | 0.440 |
Why?
|
| Alleles | 5 | 2023 | 236 | 0.430 |
Why?
|
| Memory, Episodic | 3 | 2018 | 128 | 0.430 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 35 | 0.420 |
Why?
|
| Health Surveys | 4 | 2021 | 99 | 0.410 |
Why?
|
| Models, Statistical | 3 | 2021 | 135 | 0.400 |
Why?
|
| Attention | 6 | 2023 | 145 | 0.400 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 10 | 0.390 |
Why?
|
| Gambling | 1 | 2011 | 8 | 0.390 |
Why?
|
| Dancing | 2 | 2021 | 7 | 0.390 |
Why?
|
| Case-Control Studies | 9 | 2023 | 662 | 0.380 |
Why?
|
| Models, Psychological | 1 | 2011 | 71 | 0.380 |
Why?
|
| Down Syndrome | 1 | 2011 | 10 | 0.380 |
Why?
|
| Brain Chemistry | 1 | 2011 | 46 | 0.370 |
Why?
|
| Crime | 2 | 2021 | 10 | 0.370 |
Why?
|
| Biomarkers | 4 | 2021 | 733 | 0.360 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 210 | 0.350 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2010 | 2 | 0.350 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 230 | 0.340 |
Why?
|
| Chicago | 3 | 2021 | 943 | 0.340 |
Why?
|
| Sex Characteristics | 2 | 2022 | 144 | 0.340 |
Why?
|
| Reaction Time | 6 | 2023 | 127 | 0.330 |
Why?
|
| Neural Inhibition | 2 | 2014 | 11 | 0.330 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 258 | 0.310 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 356 | 0.300 |
Why?
|
| Myelin Sheath | 2 | 2021 | 17 | 0.300 |
Why?
|
| Amnesia | 5 | 2020 | 29 | 0.290 |
Why?
|
| Self Report | 3 | 2023 | 231 | 0.280 |
Why?
|
| Learning | 2 | 2018 | 80 | 0.280 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 28 | 0.270 |
Why?
|
| Language | 3 | 2021 | 79 | 0.270 |
Why?
|
| Visual Perception | 2 | 2020 | 48 | 0.270 |
Why?
|
| Young Adult | 7 | 2021 | 2063 | 0.270 |
Why?
|
| Hospitalization | 2 | 2019 | 337 | 0.270 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 818 | 0.260 |
Why?
|
| Nerve Net | 5 | 2018 | 51 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2022 | 429 | 0.260 |
Why?
|
| Prevalence | 4 | 2021 | 499 | 0.260 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 275 | 0.250 |
Why?
|
| Problem Solving | 2 | 2009 | 47 | 0.240 |
Why?
|
| Discrimination Learning | 1 | 2004 | 2 | 0.230 |
Why?
|
| Color Perception | 1 | 2004 | 5 | 0.230 |
Why?
|
| Models, Neurological | 3 | 2018 | 29 | 0.230 |
Why?
|
| Temporal Lobe | 3 | 2018 | 103 | 0.230 |
Why?
|
| Arousal | 1 | 2004 | 44 | 0.230 |
Why?
|
| Autistic Disorder | 2 | 2014 | 48 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 1133 | 0.220 |
Why?
|
| Postmenopause | 1 | 2023 | 62 | 0.220 |
Why?
|
| Intelligence Tests | 2 | 2015 | 16 | 0.210 |
Why?
|
| Time Factors | 2 | 2019 | 1672 | 0.210 |
Why?
|
| Research Design | 2 | 2021 | 219 | 0.210 |
Why?
|
| Adolescent | 6 | 2021 | 2401 | 0.200 |
Why?
|
| Fraud | 1 | 2022 | 24 | 0.200 |
Why?
|
| Psychometrics | 2 | 2021 | 270 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 76 | 0.200 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 583 | 0.200 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 335 | 0.200 |
Why?
|
| Awareness | 1 | 2002 | 41 | 0.200 |
Why?
|
| Regression Analysis | 5 | 2018 | 300 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 238 | 0.190 |
Why?
|
| Facial Expression | 2 | 2012 | 16 | 0.190 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2023 | 120 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 100 | 0.190 |
Why?
|
| Social Identification | 1 | 2021 | 7 | 0.190 |
Why?
|
| Social Networking | 1 | 2021 | 11 | 0.190 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 12 | 0.180 |
Why?
|
| Accelerometry | 2 | 2021 | 94 | 0.180 |
Why?
|
| Emotions | 2 | 2012 | 89 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 320 | 0.180 |
Why?
|
| Southeastern United States | 1 | 2020 | 10 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2022 | 3807 | 0.180 |
Why?
|
| Midwestern United States | 1 | 2020 | 71 | 0.180 |
Why?
|
| Organ Size | 3 | 2023 | 107 | 0.180 |
Why?
|
| Wechsler Scales | 3 | 2006 | 14 | 0.180 |
Why?
|
| Mental Status Schedule | 3 | 2011 | 120 | 0.180 |
Why?
|
| Space Perception | 1 | 2020 | 26 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 360 | 0.170 |
Why?
|
| HIV Infections | 2 | 2021 | 890 | 0.170 |
Why?
|
| Judgment | 1 | 2019 | 9 | 0.170 |
Why?
|
| Acute Disease | 2 | 2012 | 231 | 0.170 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 30 | 0.170 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 33 | 0.170 |
Why?
|
| Disabled Persons | 1 | 2021 | 135 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 341 | 0.170 |
Why?
|
| Patient Selection | 1 | 2021 | 246 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 111 | 0.160 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 30 | 0.160 |
Why?
|
| Atrophy | 2 | 2016 | 100 | 0.160 |
Why?
|
| Financing, Personal | 1 | 2018 | 20 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 274 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1923 | 0.160 |
Why?
|
| Emergencies | 1 | 2019 | 40 | 0.160 |
Why?
|
| Energy Intake | 1 | 2019 | 73 | 0.160 |
Why?
|
| Cognitive Reserve | 1 | 2019 | 41 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2018 | 112 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 107 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2014 | 499 | 0.150 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 38 | 0.140 |
Why?
|
| Healthy Aging | 1 | 2017 | 16 | 0.140 |
Why?
|
| Phobia, Social | 1 | 2016 | 12 | 0.140 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 23 | 0.140 |
Why?
|
| Motor Skills | 1 | 2017 | 61 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 119 | 0.140 |
Why?
|
| Self-Assessment | 2 | 2020 | 32 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 549 | 0.130 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 19 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 171 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 918 | 0.130 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 130 | 0.130 |
Why?
|
| Urban Population | 1 | 2017 | 148 | 0.130 |
Why?
|
| Cytokines | 1 | 2017 | 351 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 43 | 0.120 |
Why?
|
| Parkinson Disease | 2 | 2020 | 1069 | 0.120 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 17 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2014 | 116 | 0.120 |
Why?
|
| Inflammation | 3 | 2023 | 362 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 199 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 37 | 0.110 |
Why?
|
| Animals | 2 | 2013 | 4722 | 0.110 |
Why?
|
| Visual Cortex | 1 | 2012 | 7 | 0.100 |
Why?
|
| Auditory Cortex | 1 | 2012 | 3 | 0.100 |
Why?
|
| Oxygen | 1 | 2012 | 87 | 0.100 |
Why?
|
| Language Tests | 2 | 2021 | 29 | 0.100 |
Why?
|
| Photic Stimulation | 3 | 2020 | 44 | 0.100 |
Why?
|
| Reward | 1 | 2011 | 34 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 53 | 0.100 |
Why?
|
| Social Class | 2 | 2022 | 70 | 0.100 |
Why?
|
| Inositol | 1 | 2011 | 7 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2011 | 15 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 45 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 5 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2010 | 22 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 782 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 83 | 0.090 |
Why?
|
| Weight Loss | 2 | 2023 | 117 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2011 | 489 | 0.080 |
Why?
|
| Medicare | 2 | 2019 | 127 | 0.080 |
Why?
|
| Neuropathology | 2 | 2019 | 87 | 0.080 |
Why?
|
| Cues | 2 | 2011 | 60 | 0.080 |
Why?
|
| Comorbidity | 1 | 2009 | 507 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2011 | 53 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 57 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2007 | 88 | 0.070 |
Why?
|
| Lewy Bodies | 2 | 2019 | 206 | 0.070 |
Why?
|
| HIV-1 | 1 | 2010 | 459 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 46 | 0.070 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 20 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 18 | 0.060 |
Why?
|
| Limbic System | 1 | 2004 | 11 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 830 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 72 | 0.060 |
Why?
|
| Reproduction | 1 | 2023 | 12 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 36 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 15 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 25 | 0.050 |
Why?
|
| Age of Onset | 2 | 2013 | 111 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 64 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 32 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 32 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 229 | 0.050 |
Why?
|
| Maze Learning | 1 | 2002 | 17 | 0.050 |
Why?
|
| Boston | 1 | 2022 | 28 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2022 | 12 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 78 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 403 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 47 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 19 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 159 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 33 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 99 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 79 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 3 | 0.050 |
Why?
|
| South America | 1 | 2020 | 4 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2021 | 23 | 0.050 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2020 | 3 | 0.050 |
Why?
|
| Amino Acids | 2 | 2010 | 22 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 173 | 0.040 |
Why?
|
| New York | 1 | 2020 | 10 | 0.040 |
Why?
|
| California | 1 | 2020 | 31 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 22 | 0.040 |
Why?
|
| Orientation | 1 | 2020 | 8 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 259 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2019 | 23 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 68 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 41 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 407 | 0.040 |
Why?
|
| Amyloid | 1 | 2018 | 58 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2019 | 104 | 0.040 |
Why?
|
| Serial Learning | 1 | 2018 | 8 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 50 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 240 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 85 | 0.040 |
Why?
|
| Comoros | 1 | 2017 | 1 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 155 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2017 | 16 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 199 | 0.040 |
Why?
|
| Sphygmomanometers | 1 | 2017 | 3 | 0.040 |
Why?
|
| Massachusetts | 1 | 2017 | 19 | 0.040 |
Why?
|
| tau Proteins | 1 | 2018 | 229 | 0.040 |
Why?
|
| Autopsy | 1 | 2018 | 351 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 61 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 112 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 234 | 0.030 |
Why?
|
| Czech Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 29 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 452 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 24 | 0.030 |
Why?
|
| Semantics | 1 | 2014 | 20 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 99 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 17 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 13 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 10 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 10 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 23 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 70 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 64 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 84 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 98 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 196 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 97 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 409 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 318 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 178 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 96 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 333 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3659 | 0.010 |
Why?
|